Literature DB >> 3973025

Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.

A Rubinstein, J C Gibson, J R Paterniti, G Kakis, A Little, H N Ginsberg, W V Brown.   

Abstract

In normal subjects, apolipoprotein E (apo E) is present on very low density lipoproteins (VLDL) (fraction I) and on particles of a size intermediate between VLDL and low density lipoproteins (LDL) (fraction II). The major portion of apo E is, however, on particles smaller than LDL but larger than the average high density lipoproteins (HDL) (fraction III). To investigate the possible role of the vascular lipases in determining this distribution of apo E among the plasma lipoproteins, we studied subjects with primary deficiency of either hepatic lipase or of lipoprotein lipase and compared them with normal subjects. Subjects with familial hepatic triglyceride lipase deficiency (n = 2) differ markedly from normal in that fraction II is the dominant apo E-containing group of lipoproteins. When lipolysis of VLDL was enhanced in these subjects upon release of lipoprotein lipase by intravenous heparin, a shift of the apo E from VLDL into fractions II and III was observed. In contrast, apolipoproteins CII and CIII (apo CII and CIII, respectively) did not accumulate in intermediate-sized particles but were shifted markedly from triglyceride rich lipoproteins to HDL after treatment with heparin. In subjects with primary lipoprotein lipase deficiency (n = 4), apo E was confined to fractions I and III. Release of hepatic triglyceride lipase by heparin injection in these subjects produced a shift of apo E from fraction I to III with no significant increase in fraction II. This movement of apo E from large VLDL and chylomicron-sized particles occurred with little hydrolysis of triglyceride and no significant shift of apo CII or CIII into HDL from triglyceride rich lipoproteins. When both lipoprotein lipase and hepatic triglyceride lipase were released by intravenous heparin injection into normal subjects (n = 3), fraction I declined and the apo E content of fraction III increased by an equivalent amount. Either moderate or no change was noted in the intermediate sized particles (fraction II). These data strongly support the hypothesis that fraction II is the product of the action of lipoprotein lipase upon triglyceride rich lipoproteins and is highly dependent on hepatic triglyceride lipase for its further catabolism. In addition, the hydrolysis by hepatic triglyceride lipase of triglyceride rich lipoproteins in general results in a preferential loss of apo E and its transfer to a specific group of large HDL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973025      PMCID: PMC423564          DOI: 10.1172/JCI111751

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Direct measurement of apoprotein C-III specific activity in 125I-labeled very low density lipoproteins using immunoaffinity chromatography.

Authors:  P R Bukberg; N A Le; H N Ginsberg; J C Gibson; L C Goldman; W V Brown
Journal:  J Lipid Res       Date:  1983-09       Impact factor: 5.922

2.  Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects.

Authors:  J C Gibson; A Rubinstein; P R Bukberg; W V Brown
Journal:  J Lipid Res       Date:  1983-07       Impact factor: 5.922

3.  Effects of heparin infusion on plasma lipoproteins in subjects with lipoprotein lipase deficiency. Evidence for a role of hepatic endothelial lipase in the metabolism of high-density lipoprotein subfractions in man.

Authors:  S N Rao; C Cortese; N E Miller; Y Levy; B Lewis
Journal:  FEBS Lett       Date:  1982-12-13       Impact factor: 4.124

4.  Changes in high-density lipoprotein protein composition after heparin-induced lipolysis.

Authors:  J C LaRosa; R I Levy; W V Brown; D S Fredrickson
Journal:  Am J Physiol       Date:  1971-03

5.  Changes in the plasma lipoprotein distribution of apolipoproteins C-II, C-III1, C-III2 and apolipoprotein B after heparin-induced lipolysis.

Authors:  P J Nestel; M W Huff; T Billington; N H Fidge
Journal:  Biochim Biophys Acta       Date:  1982-07-20

6.  Dynamics of apolipoprotein E metabolism in humans.

Authors:  C B Blum
Journal:  J Lipid Res       Date:  1982-12       Impact factor: 5.922

7.  Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; J R Paterniti; H N Ginsberg; F T Lindgren; W V Brown
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

8.  Very low density lipoprotein triglyceride transport in type IV hyperlipoproteinemia and the effects of carbohydrate-rich diets.

Authors:  S H Quarfordt; A Frank; D M Shames; M Berman; D Steinberg
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

9.  Liver lipase and high-density lipoprotein. Lipoprotein changes after incubation of human serum with rat liver lipase.

Authors:  P H Groot; L M Scheek; H Jansen
Journal:  Biochim Biophys Acta       Date:  1983-05-16

10.  Formation of cholesterol- and apoprotein E-enriched high density lipoproteins in vitro.

Authors:  V Gordon; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1983-05-25       Impact factor: 5.157

View more
  10 in total

1.  Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.

Authors:  Jeremy D Furtado; Mark K Wedel; Frank M Sacks
Journal:  J Lipid Res       Date:  2012-02-02       Impact factor: 5.922

2.  Interactive effects of APOE haplotype, sex, and exercise on postheparin plasma lipase activities.

Authors:  Richard L Seip; Robert F Zoeller; Theodore J Angelopoulos; James Salonia; Cherie Bilbie; Niall M Moyna; Mary P Miles; Paul S Visich; Linda S Pescatello; Paul M Gordon; Gregory J Tsongalis; Linda Bausserman; Paul D Thompson
Journal:  J Appl Physiol (1985)       Date:  2011-01-20

3.  High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.

Authors:  Mariko Tani; Katalin V Horvath; Benoit Lamarche; Patrick Couture; John R Burnett; Ernst J Schaefer; Bela F Asztalos
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

4.  Association of plasma lipoproteins with postheparin lipase activities.

Authors:  I J Goldberg; J J Kandel; C B Blum; H N Ginsberg
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

5.  Use of a fluorescent radiolabeled triacylglycerol as a substrate for lipoprotein lipase and hepatic triglyceride lipase.

Authors:  N Dousset; A Negre; R Salvayre; P Rogalle; Q Q Dang; L Douste-Blazy
Journal:  Lipids       Date:  1988-06       Impact factor: 1.880

6.  Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; H N Ginsberg; R M Krauss; F T Lindgren
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

7.  Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 1. ApoE distribution between lipoproteins.

Authors:  Alexander D Dergunov; Anne Ponthieux; Maxim V Mel'kin; Daniel Lambert; Sophie Visvikis-Siest; Gerard Siest
Journal:  Mol Cell Biochem       Date:  2009-01-13       Impact factor: 3.396

8.  Effects of dietary phospholipid level in cobia (Rachycentron canadum) larvae: growth, survival, plasma lipids and enzymes of lipid metabolism.

Authors:  J Niu; Y J Liu; L X Tian; K S Mai; H J Yang; C X Ye; Y Zhu
Journal:  Fish Physiol Biochem       Date:  2007-06-07       Impact factor: 2.794

9.  Coexistence of abnormalities of hepatic lipase and lipoprotein lipase in a large family.

Authors:  J H Auwerx; S P Babirak; J E Hokanson; G Stahnke; H Will; S S Deeb; J D Brunzell
Journal:  Am J Hum Genet       Date:  1990-03       Impact factor: 11.025

10.  Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes.

Authors:  Hidenori Bando; Shinji Taneda; Naoki Manda
Journal:  JMA J       Date:  2021-03-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.